Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Abstract Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2−) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly imp...

Full description

Saved in:
Bibliographic Details
Main Authors: Niklas Gremke, Isabelle Besong, Alina Stroh, Luise von Wichert, Marie Witt, Sabrina Elmshäuser, Michael Wanzel, Martin F. Fromm, R. Verena Taudte, Sabine Schmatloch, Thomas Karn, Mattea Reinisch, Nader Hirmas, Sibylle Loibl, Thomas Wündisch, Anne-Sophie Litmeyer, Paul Jank, Carsten Denkert, Sebastian Griewing, Uwe Wagner, Thorsten Stiewe
Format: Article
Language:English
Published: Nature Publishing Group 2025-03-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-025-02180-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items